IP Library Granted Patent US 10,512,666
Granted Patent B2
US 10,512,666 · App. 16/047,490 · Granted Dec 24, 2019

Peptides for prevention of HIV infection

Inventor: Ivan V. Korendovych (Syracuse, NY)
Assignee: SYRACUSE UNIVERSITY
A61K38/10A61K9/0014
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,512,666
App. No.
16/047,490
Granted
Dec 24, 2019
Kind
B2
Abstract

Two peptides that can selectively bind to SEVI and block the enhanced infectivity that results from the interaction of SEVI with HIV. The two peptides comprise the amino acid sequences FEEIVQEIEDFLENLV (SEQ. ID NO: 1) and GIGAVLEVLTTGLPALISWIEEEEQQ (SEQ. ID. NO: 2). The peptides may be administered topically, either alone or in combination with other prophylactics, agents, etc.

Claims (8)

1. A compound, comprising an artificial peptide sequence that binds to semen enhancer of virus infection (SEVI) amyloid fibrils of prostatic acid phosphatase (PAP) but does not bind to non-aggregated PAP, wherein the artificial peptide sequence is selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 2.

2. The compound of claim 1 , wherein the artificial peptide sequence is SEQ ID NO: 1.

3. The compound of claim 2 , wherein the artificial peptide sequence is SEQ ID NO: 2.

4. A composition comprising the compound of claim 1 combined with a prophylactic.

5. A composition comprising the compound of claim 1 combined with a topical agent.

6. A combination product, comprising a first artificial peptide sequence that binds to semen enhancer of virus infection (SEVI) amyloid fibrils of prostatic acid phosphatase (PAP) but does not bind to non-aggregated PAP combined with a second artificial peptide sequence that binds to SEVI but does not bind to non-aggregated PAP, wherein the first artificial peptide sequence is SEQ ID NO: 1 and the second artificial peptide sequence is SEQ ID NO: 2.

7. The combination product of claim 6 , wherein the first artificial peptide sequence and the second artificial peptide sequence are combined with a topical agent.

8. The combination product of claim 6 , wherein the first artificial peptide sequence and the second artificial peptide sequence are combined with a prophylactic.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2018
From: KORENDOVYCH, IVAN V.
To: SYRACUSE UNIVERSITY
Reel/Frame 046484/0644 →
Continuity (2)
Provisional Application 62539774 · Aug 1, 2017
Related Publication 20190038702A1 · Feb 7, 2019